Beta Cell Therapy in Diabetes
Category
FP7 Project with U.S. partner
Short name and number
BetaCellTherapy (241883)
Area
Health
Description
Type 1 diabetes is a serious chronic disease with major health risks and heavy burden on patients and society. It is caused by massive immune-mediated loss of insulin-producing beta cells in the pancreas that can so far not be locally corrected. A cellular allotransplant in the liver can install a new beta cell mass but the size is insufficient and the procedure faces limitations of donor shortage, inaccessibility of the implants, risks of associated immunosuppression.
Participating Countries
Belgium, Denmark, France, Italy, The Netherlands, United Kingdom, United States, Israel, Switzerland and Norway.
Name of US Partner
NOVOCELL INC
Contact
VRIJE UNIVERSITEIT BRUSSEL